• 諮詢熱線+852 3480 8393

Logo
  • 首頁
  • 公司介紹
    • 背景
    • 免疫治療日本
    • 免疫治療香港
    • 腫瘤科醫生
  • 免疫細胞治療
    • 免疫細胞治療/自體免疫療法
    • 樹突狀細胞/DC疫苗療法
    • 自然殺傷細胞/NK細胞療法
    • 淋巴因子活化殺傷細胞(殺手T細胞)療法
    • 免疫治療成功率
    • 免疫治療副作用
    • 免疫治療費用
  • 醫生介紹
    • 日本
    • 香港
  • 癌症預防/防復發
    • 癌症復發率
    • 癌症預防
  • 新聞及臨床報告
    • 新聞
    • 臨床醫學報告
  • 聯絡我們

新聞及臨床報告

  • 首頁
  • 新聞及臨床報告
  • 臨床醫學報告
首頁 > 新聞及臨床報告 > 臨床醫學報告 > Enhancing Dendritic Cell Therapy in Solid Tumors with Immunomodulating Conventional Treatment

Enhancing Dendritic Cell Therapy in Solid Tumors with Immunomodulating Conventional Treatment

  • Mol Ther Oncolytics
  • 2022-06-17
  • 0 次瀏覽

https://pubmed.ncbi.nlm.nih.gov/31020037/ 


Abstract

Dendritic cells (DCs) are the most potent antigen-presenting cells and are the key initiator of tumor-specific immune responses. These characteristics are exploited by DC therapy, where DCs are ex vivo loaded with tumor-associated antigens (TAAs) and used to induce tumor-specific immune responses. Unfortunately, clinical responses remain limited to a proportion of the patients. Tumor characteristics and the immunosuppressive tumor microenvironment (TME) of the tumor are likely hampering efficacy of DC therapy. Therefore, reducing the immunosuppressive TME by combining DC therapy with other treatments could be a promising strategy. Initially, conventional cancer therapies, such as chemotherapy and radiotherapy, were thought to specifically target cancerous cells. Recent insights indicate that these therapies additionally augment tumor immunity by targeting immunosuppressive cell subsets in the TME, inducing immunogenic cell death (ICD), or blocking inhibitory molecules. Therefore, combining DC therapy with registered therapies such as chemotherapy, radiotherapy, or checkpoint inhibitors could be a promising treatment strategy to improve the efficacy of DC therapy. In this review, we evaluate various clinical applicable combination strategies to improve the efficacy of DC therapy.


Source: Belderbos RA, Aerts JGJV, Vroman H. Enhancing Dendritic Cell Therapy in Solid Tumors with Immunomodulating Conventional Treatment. Mol Ther Oncolytics. 2019 Mar 27;13:67-81. doi: 10.1016/j.omto.2019.03.007. PMID: 31020037; PMCID: PMC6475716.


上一篇:Antigen presentation by dendritic cells and their instruction of CD4+ T helper cell responses 下一篇:Targeted Cancer Therapy by Dendritic Cell Vaccine

欄目分類

  • 新聞 7
  • 臨床醫學報告 13

熱門文章

  • Targeting dendritic cells in pancreatic ductal adenocarcinoma
    2022-06-17
  • Modified Immunotherapy Approach Shows Promise for Leukemia Subscribe
    2022-06-17
  • Dendritic cell activation enhances anti-PD-1 mediated immunotherapy against glioblastoma
    2022-06-17
  • Targeted Cancer Therapy by Dendritic Cell Vaccine
    2022-06-17
  • Dendritic Cell–Based Immunotherapy: State of the Art and Beyond
    2022-06-17
  • Enhancing Dendritic Cell Therapy in Solid Tumors with Immunomodulating Conventional Treatment
    2022-06-17
  • NK cell-based cancer immunotherapy: from basic biology to clinical development
    2022-06-17
  • WT1 (Wilms' Tumor Gene 1): Biology and Cancer Immunotherapy
    2022-06-17
  • Cancer immunotherapy via dendritic cells
    2022-05-05
Logo
  • 郵箱:info@asiaimmune.com
  • 電話:+852 3480 8393

免疫細胞治療

  • 免疫細胞治療/自體免疫療法
  • 樹突狀細胞/DC疫苗療法
  • 自然殺傷細胞/NK細胞療法
  • 淋巴因子活化殺傷細胞(殺手T細胞)療法
  • 免疫治療成功率
  • 免疫治療副作用
  • 免疫治療費用

合作機構

  • 日本新橫濱加藤醫院

公司地址

  • 九龍尖沙咀漢口道28號亞太中心8樓812室
  • +852 3480 8393

Copyright © 2022. Designed by Asia Immunotherapy Company Limited.